USP21/YBX1/HIF1-α promotes the progression of prostate cancer
USP21 promotes PCa malignancy by interacting with YBX1 to upregulate HIF1-α expression. These findings suggest Bay-805 as a promising therapeutic candidate for PCa.
Authors
- Yadong Guo (ORCID: https://orcid.org/0000-0002-6684-7015)
- Libin Zou
- Dan Huang (ORCID: https://orcid.org/0000-0001-9079-0955)
- Jiang Geng (ORCID: https://orcid.org/0000-0002-7202-2167)
- Cheng Jiang (ORCID: https://orcid.org/0000-0003-1730-8581)
- Donghui Shi (ORCID: https://orcid.org/0000-0001-5301-368X)
- Xudong Yao (ORCID: https://orcid.org/0000-0001-7234-3940)
- Zhuoran Gu
- Yue Zhang (ORCID: https://orcid.org/0000-0002-0789-4970)
- Liu Ji (ORCID: https://orcid.org/0000-0002-4233-4821)
- Yifan Chen (ORCID: https://orcid.org/0000-0002-8433-3210)
- Shiyu Mao (ORCID: https://orcid.org/0000-0003-4652-6828)
- Feng Qi (ORCID: https://orcid.org/0000-0003-3221-011X)
- Junfeng Zhang (ORCID: https://orcid.org/0000-0003-4214-0864)
- Wentao Zhang (ORCID: https://orcid.org/0009-0005-0091-1749)
Institutions
- Tongji University (CN)
- Shanghai Cancer Institute (CN)
- Jiangsu Cancer Hospital (CN)
- Shanghai Tenth People's Hospital (CN)
- The Fifth People’s Hospital of Suzhou (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1186/s12967-025-07199-3
- Citations
- 3
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42